TF and prostate cancer: CK2 inhibition (DMAT, TF, TBB, TBCA, siRNA, apigenin, and KI-CK2α) reduces cell proliferation in prostate cancer cell lines [49,142,143,144,145,146], and TF, CX-4945, DMAT, TBB, TBCA, and apigenin increase apoptosis [49,142,146,147,148,149,150].